Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pre-Operative Tucatinib for Surgically Resected HER2+ Brain Metastases
NCT05892068Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- May 2023
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tucatinib in brain metastasis (BM), breast cancer, metastatic colorectal cancer (mCRC), Esophagogastric Cancer, sponsored by Memorial Sloan Kettering Cancer Center. Started May 2023; status: active, not recruiting.
02
Drugs
tucatinib
03
Conditions
brain metastasis (BM)breast cancermetastatic colorectal cancer (mCRC)Esophagogastric Cancer
Beyond the preview
Go deeper on NCT05892068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05892068.